Advocating for Impact: Deciphering CMS’s Telehealth Changes

Jillanne Schulte Wall, ASHP Senior Director, Health & Regulatory Policy and Mary Ann Kliethermes, ASHP Director, Medication Safety & Quality, discuss CMS’s recent telehealth changes, the resulting regulatory flexibilities that are helpful to our members and their patients, and ASHP’s next steps on telehealth advocacy.

The information presented during the podcast reflects solely the opinions of the presenter.  The information and materials are not, and are not intended as, a comprehensive source of drug information on this topic. The contents of the podcast have not been reviewed by ASHP, and should neither be interpreted as the official policies of ASHP, nor an endorsement of any product(s), nor should they be considered as a substitute for the professional judgment of the pharmacist or physician.